These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
312 related articles for article (PubMed ID: 12874015)
1. Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide. Nakahara S; Tsunoda T; Baba T; Asabe S; Tahara H Cancer Res; 2003 Jul; 63(14):4112-8. PubMed ID: 12874015 [TBL] [Abstract][Full Text] [Related]
2. Streptococcal preparation OK-432 promotes the capacity of dendritic cells (DCs) to prime carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocyte responses induced with genetically modified DCs that express CEA. Ojima T; Iwahashi M; Nakamura M; Matsuda K; Nakamori M; Ueda K; Naka T; Katsuda M; Miyazawa M; Iida T; Yamaue H Int J Oncol; 2008 Feb; 32(2):459-66. PubMed ID: 18202769 [TBL] [Abstract][Full Text] [Related]
3. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation. Okamoto M; Furuichi S; Nishioka Y; Oshikawa T; Tano T; Ahmed SU; Takeda K; Akira S; Ryoma Y; Moriya Y; Saito M; Sone S; Sato M Cancer Res; 2004 Aug; 64(15):5461-70. PubMed ID: 15289356 [TBL] [Abstract][Full Text] [Related]
4. Efficient induction of specific cytotoxic T lymphocytes to tumor rejection peptide using functional matured 2 day-cultured dendritic cells derived from human monocytes. Tanaka F; Yamaguchi H; Haraguchi N; Mashino K; Ohta M; Inoue H; Mori M Int J Oncol; 2006 Nov; 29(5):1263-8. PubMed ID: 17016660 [TBL] [Abstract][Full Text] [Related]
6. Preparation of fully activated dendritic cells capable of priming tumor-specific cytotoxic T lymphocytes in patients with metastatic cancer using penicillin-killed streptococcus pyogenes (OK432) and anti-CD40 antibody. Kontani K; Teramoto K; Ozaki Y; Sawai S; Tezuka N; Ishida H; Kajino K; Fujino S; Yamauchi A; Taguchi O; Kannagi R; Yokomise H; Ogasawara K Oncol Rep; 2007 Apr; 17(4):895-902. PubMed ID: 17342333 [TBL] [Abstract][Full Text] [Related]
7. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen. Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645 [TBL] [Abstract][Full Text] [Related]
8. CD11c+ blood dendritic cells induce antigen-specific cytotoxic T lymphocytes with similar efficiency compared to monocyte-derived dendritic cells despite higher levels of MHC class I expression. Radford KJ; Turtle CJ; Kassianos AJ; Hart DN J Immunother; 2006; 29(6):596-605. PubMed ID: 17063122 [TBL] [Abstract][Full Text] [Related]
9. Regulation of dendritic cell interleukin-12 secretion by tumour cell necrosis. Kandil H; Bachy V; Williams DJ; Helmi R; Gotch FM; Ibrahim MA Clin Exp Immunol; 2005 Apr; 140(1):54-64. PubMed ID: 15762875 [TBL] [Abstract][Full Text] [Related]
10. Induction of cytolytic T lymphocytes against pediatric solid tumors in vitro using autologous dendritic cells pulsed with necrotic primary tumor. Shilyansky J; Jacobs P; Doffek K; Sugg SL J Pediatr Surg; 2007 Jan; 42(1):54-61; discussion 61. PubMed ID: 17208541 [TBL] [Abstract][Full Text] [Related]
11. Effects of monomethylfumarate on dendritic cell differentiation. Litjens NH; Rademaker M; Ravensbergen B; Thio HB; van Dissel JT; Nibbering PH Br J Dermatol; 2006 Feb; 154(2):211-7. PubMed ID: 16433787 [TBL] [Abstract][Full Text] [Related]
12. A functional comparison of mature human dendritic cells prepared in fluorinated ethylene-propylene bags or polystyrene flasks. Kurlander RJ; Tawab A; Fan Y; Carter CS; Read EJ Transfusion; 2006 Sep; 46(9):1494-504. PubMed ID: 16965575 [TBL] [Abstract][Full Text] [Related]
13. [Immunotherapeutic efficacy of both helper T lymphocytes and cytotoxic T lymphocytes epitopes augmented dendritic cells tumor vaccine on gastric cancer]. Li Q; Zhang Y; Chen XH; Cao WX; Gu QL; Zhu ZG; Liu BY Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Mar; 9(2):148-51. PubMed ID: 16555158 [TBL] [Abstract][Full Text] [Related]
14. Induction of cytotoxic T lymphocytes against human cancer cell lines using dendritic cell-tumor cell hybrids generated by a newly developed electrofusion technique. Imura K; Ueda Y; Hayashi T; Itoh T; Shimizu K; Tamai H; Yano Y; Naito K; Kohara J; Nakane K; Matsuura Y; Takeda A; Takeda T; Kawai K; Yamagishi H Int J Oncol; 2006 Sep; 29(3):531-9. PubMed ID: 16865268 [TBL] [Abstract][Full Text] [Related]
15. Generation of tumor-specific T-lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells. Hoffmann TK; Meidenbauer N; Dworacki G; Kanaya H; Whiteside TL Cancer Res; 2000 Jul; 60(13):3542-9. PubMed ID: 10910067 [TBL] [Abstract][Full Text] [Related]
16. A novel approach to induce human DCs from monocytes by triggering 4-1BBL reverse signaling. Ju S; Ju S; Ge Y; Qiu H; Lu B; Qiu Y; Fu J; Liu G; Wang Q; Hu Y; Shu Y; Zhang X Int Immunol; 2009 Oct; 21(10):1135-44. PubMed ID: 19684160 [TBL] [Abstract][Full Text] [Related]
17. Human dendritic cells very efficiently present a heterologous antigen expressed on the surface of recombinant gram-positive bacteria to CD4+ T lymphocytes. Corinti S; Medaglini D; Cavani A; Rescigno M; Pozzi G; Ricciardi-Castagnoli P; Girolomoni G J Immunol; 1999 Sep; 163(6):3029-36. PubMed ID: 10477566 [TBL] [Abstract][Full Text] [Related]
18. The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells. Tsang KY; Zhu M; Even J; Gulley J; Arlen P; Schlom J Cancer Res; 2001 Oct; 61(20):7568-76. PubMed ID: 11606396 [TBL] [Abstract][Full Text] [Related]
19. Toll-like receptor signaling in anti-cancer immunity. Okamoto M; Sato M J Med Invest; 2003 Feb; 50(1-2):9-24. PubMed ID: 12630564 [TBL] [Abstract][Full Text] [Related]
20. Polarization of naive T cells into Th1 or Th2 by distinct cytokine-driven murine dendritic cell populations: implications for immunotherapy. Feili-Hariri M; Falkner DH; Morel PA J Leukoc Biol; 2005 Sep; 78(3):656-64. PubMed ID: 15961574 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]